About MediciNova (NASDAQ:MNOV)
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500
Debt
Debt-to-Equity RatioN/A
Current Ratio53.42
Quick Ratio53.42
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book7.93
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-11,160,000.00
Net MarginsN/A
Return on Equity-27.90%
Return on Assets-25.35%
Miscellaneous
Employees9
Outstanding Shares41,130,000
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.
What price target have analysts set for MNOV?
1 brokerages have issued twelve-month target prices for MediciNova's shares. Their predictions range from $22.00 to $22.00. On average, they expect MediciNova's stock price to reach $22.00 in the next twelve months. View Analyst Ratings for MediciNova.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), Deciphera Pharmaceuticals (DCPH), Impax Laboratories (IPXL), IMMURON Ltd/S (IMRN), ImmunoGen (IMGN), Uniqure (QURE), Theravance Biopharma (TBPH), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Revance Therapeutics (RVNC), Retrophin (RTRX) and Intra-Cellular Therapies (ITCI).
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 68)
- Mr. Ryan J. Selhorn, CFO & Principal Accounting Officer (Age 36)
- Mr. Masatsune Okajima, Head of Japanese Office and VP (Age 50)
- Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 52)
- Mr. Geoffrey G. O'Brien J.D., M.B.A., VP (Age 49)
Has MediciNova been receiving favorable news coverage?
Media stories about MNOV stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MediciNova earned a media sentiment score of 0.10 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.61 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are MediciNova's major shareholders?
MediciNova's stock is owned by many different of institutional and retail investors. Top institutional investors include SATOMI HAJIME (5.30%), BlackRock Inc. (5.23%), Sphera Funds Management LTD. (1.53%), Northern Trust Corp (1.01%), Wexford Capital LP (0.30%) and Jane Street Group LLC (0.23%). Company insiders that own MediciNova stock include Geoffrey Obrien, Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.
Which institutional investors are selling MediciNova stock?
Which institutional investors are buying MediciNova stock?
MNOV stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., BlackRock Inc., Wexford Capital LP, Jane Street Group LLC, Northern Trust Corp, Sofinnova Ventures Inc, PNC Financial Services Group Inc. and MetLife Investment Advisors LLC. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova.
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $8.49.
How big of a company is MediciNova?
MediciNova has a market capitalization of $349.19 million. MediciNova employs 9 workers across the globe.
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
